Pharvaris Netherlands B.v.
Clinical trials sponsored by Pharvaris Netherlands B.v., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could stop dangerous swelling attacks in hereditary angioedema Results expected Jun 2027 (estimated)
- New pill could stop and treat dangerous swelling attacks Results expected Jun 2027 (estimated)
-
New daily pill could stop painful swelling attacks for HAE patients
Disease control OngoingThis Phase 3 trial tests whether a once-daily pill called deucrictibant can prevent sudden swelling attacks in people aged 12 and older with hereditary angioedema (HAE). Participants receive either the drug or a placebo for 24 weeks, and researchers count how many attacks occur. …
Phase 3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New pill could stop dangerous swelling attacks in hereditary angioedema
Symptom relief By invitation onlyThis study tests a pill called deucrictibant for quickly treating swelling attacks in people with hereditary angioedema (HAE), including life-threatening throat swelling. About 150 adults who have had HAE attacks before will take the drug as needed and be monitored for safety and…
Phase 2/3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC